Host apolipoprotein b messenger RNA‐editing enzyme catalytic polypeptide‐like 3G is an innate defensive factor and drug target against hepatitis C virus

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hepatology

• Publication date

  2011-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/hep.24160PMID 21480314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA

  2010cited by this paper
• Interferon-Based Therapy for Chronic Hepatitis C: Current and Future Perspectives

  2010cited by this paper
• Small Molecular Compounds Inhibit HIV-1 Replication through Specifically Stabilizing APOBEC3G*

  2010influential reference
• Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis

  2010cited by this paper
• High level expression of the anti-retroviral protein APOBEC3G is induced by influenza A virus but does not confer antiviral activity

  2009cited by this paper
• Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

  2009cited by this paper
• Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

  2009cited by this paper
• Antiviral resistance and specifically targeted therapy for HCV (STAT‐C)

  2009cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009cited by this paper
• Deaminase-Independent Inhibition of Parvoviruses by the APOBEC3A Cytidine Deaminase

  2009cited by this paper
• Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.

  2009cited by this paper
• Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

  2009cited by this paper
• Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

  2009cited by this paper
• Hepatitis C therapies

  2008cited by this paper
• Small-molecule inhibition of HIV-1 Vif

  2008influential reference
• Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H.

  2008cited by this paper
• Interferon-based therapy for chronic hepatitis C: current and future perspectives

  2008cited by this paper
• APOBEC3G Inhibits Elongation of HIV-1 Reverse Transcripts

  2008cited by this paper
• Enhancing immunity to HIV through APOBEC

  2008cited by this paper
• Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients

  2008cited by this paper
• APOBEC-mediated viral restriction: not simply editing?

  2007cited by this paper
• Deamination-Independent Inhibition of Hepatitis B Virus Reverse Transcription by APOBEC3G

  2007cited by this paper
• Viral hepatitis in HIV infection.

  2007cited by this paper
• Viral hepatitis in HIV infection.

  2007cited by this paper
• Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination

  2006cited by this paper
• Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

  2006cited by this paper
• High expression of APOBEC3G in patients infected with hepatitis C virus

  2006cited by this paper
• Inhibition of \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(\mathrm{tRNA}_{3}^{\mathrm{Lys}}\) \end{document}-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency

  2006cited by this paper
• APOBEC3G targets human T-cell leukemia virus type 1

  2006cited by this paper
• APOBEC3G targets human T-cell leukemia virus type 1

  2005cited by this paper
• Retrovirology BioMed Central Commentary APOBEC3G & HTLV-1: Inhibition without deamination

  2005cited by this paper
• Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

  2005cited by this paper
• Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR.

  2005cited by this paper
• Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

  2005cited by this paper
• The Interaction between HIV-1 Gag and APOBEC3G*

  2004influential reference
• Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

  2003cited by this paper
• Hypermutation of HIV-1 DNA in the Absence of the Vif Protein

  2003cited by this paper
• The Human Immunodeficiency Virus Type 1 Vif Protein Reduces Intracellular Expression and Inhibits Packaging of APOBEC3G (CEM15), a Cellular Inhibitor of Virus Infectivity

  2003cited by this paper
• An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

  2002cited by this paper
• Real-time RT-PCR for quantitation of hepatitis C virus RNA.

  2002cited by this paper
• Faculty Opinions recommendation of Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

  2002cited by this paper
• Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

  2002cited by this paper
• Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line

  1999cited by this paper
• Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

  1999cited by this paper
• Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells

  1993cited by this paper

• The Intricate Interplay between APOBEC3 Proteins and DNA Tumour Viruses

  2024cites this paper
• Subgenomic flaviviral RNAs and human proteins: in silico exploration of anti-host defense mechanisms

  2024cites this paper
• Bystander Effects and Profibrotic Interactions in Hepatic Stellate Cells during HIV and HCV Coinfection

  2024cites this paper
• Putative APOBEC3 deaminase editing in MPXV as evidence for sustained human transmission since at least 2016

  2023cites this paper
• APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016

  2023cites this paper
• APOBEC3G Is a p53-Dependent Restriction Factor in Respiratory Syncytial Virus Infection of Human Cells Included in the p53/Immune Axis

  2023cites this paper
• Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses.

  2023cites this paper
• Host-mediated RNA editing in viruses

  2023cites this paper
• Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Synthesis and structure-activity relationship study of new biaryl amide derivatives and their inhibitory effects against hepatitis C virus

  2021cites this paper
• TGF‐β isoforms inhibit hepatitis C virus propagation in transforming growth factor beta/SMAD protein signalling pathway dependent and independent manners

  2021cites this paper
• [APOBEC3s: history of an antiviral and mutagenic protein family].

  2020cites this paper
• Footprint of the host restriction factors APOBEC3 on the genome of human viruses

  2020cites this paper
• Synthesis and Bioactivity of N-(4-Chlorophenyl)-4-Methoxy-3-(Methylamino) Benzamide as a Potential Anti-HBV Agent

  2020cites this paper
• Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy

  2020cites this paper
• Medicinal chemistry strategies toward host targeting antiviral agents

  2020influential citation
• Non-Coding RNA Editing in Cancer Pathogenesis

  2020cites this paper
• APOBEC3G is a restriction factor of EV71 and mediator of IMB‐Z antiviral activity

  2019cites this paper
• Harzianoic acids A and B, new natural scaffolds with inhibitory effects against hepatitis C virus.

  2019cites this paper
• Zika virus noncoding sfRNAs sequester multiple host-derived RNA-binding proteins and modulate mRNA decay and splicing during infection

  2019influential citation
• A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.

  2019cites this paper
• Title Links between Human LINE-1 Retrotransposons and Hepatitis Virus-Related Hepatocellular Carcinoma

  2018cites this paper
• Mobile Genetic Elements in Cellular Differentiation, Genome Stability, and Cancer

  2018cites this paper
• APOBEC3G-Regulated Host Factors Interfere with Measles Virus Replication: Role of REDD1 and Mammalian TORC1 Inhibition

  2018cites this paper
• Bicyclol Attenuates Liver Inflammation Induced by Infection of Hepatitis C Virus via Repressing ROS-Mediated Activation of MAPK/NF-κB Signaling Pathway

  2018cites this paper
• The preferred nucleotide contexts of the AID/APOBEC cytidine deaminases have differential effects when mutating retrotransposon and virus sequences compared to host genes

  2017cites this paper
• Internal driving factors leading to extrahepatic manifestation of the hepatitis C virus infection

  2017cites this paper
• Protein Inhibitor of Activated STAT2 Restricts HCV Replication by Modulating Viral Proteins Degradation

  2017influential citation
• Links between Human LINE-1 Retrotransposons and Hepatitis Virus-Related Hepatocellular Carcinoma

  2016cites this paper
• Host restriction factors for hepatitis C virus.

  2016cites this paper
• Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.

  2016cites this paper
• Plumbagin, a Plant‐Derived Compound, Exhibits Antifungal Combinatory Effect with Amphotericin B against Candida albicans Clinical Isolates and Anti‐hepatitis C Virus Activity

  2016cites this paper
• CD36 is a co-receptor for hepatitis C virus E1 protein attachment

  2016cites this paper
• APOBEC4 Enhances the Replication of HIV-1

  2016cites this paper
• DNA Editing by APOBECs: A Genomic Preserver and Transformer.

  2016cites this paper
• Host APOBEC3G Protein Inhibits HCV Replication through Direct Binding at NS3

  2015cites this paper
• Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection

  2015cites this paper
• Synthesis and antiviral activity of a series of novel N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents

  2015cites this paper
• Pathogens

  2014cites this paper
• Synthesis and antiviral activity of some novel indole-2-carboxylate derivatives

  2014cites this paper
• Virus-related liver cirrhosis: molecular basis and therapeutic options.

  2014cites this paper
• Determining and utilizing the quasispecies of the hepatitis B virus in clinical applications

  2014cites this paper
• The Role of Cytidine Deaminases on Innate Immune Responses against Human Viral Infections

  2013cites this paper
• Elevation of Serum Apolipoprotein B after Successful Eradication of Hepatitis C Virus in Patients with Chronic Hepatitis C Treated by IFN-Based Therapy

  2013cites this paper
• Synthesis of novel substituted N-aryl benzamides as hA3G stabilizers and their inhibitory activities against hepatitis C virus replication

  2013cites this paper
• Elevation of Serum Apolipoprotein B after Successful Eradication of Hepatitis C Virus in Patients with Chronic Hepatitis C Treated by IFNBased Therapy

  2013cites this paper
• Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.

  2013cites this paper
• An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals

  2012cites this paper
• Liver biopsy interpretation in liver cancer

  2011cites this paper
• No transfats

  2011cites this paper
• The ethics of placebo treatment for patients with acute exacerbation of chronic hepatitis B

  2011cites this paper
• Detection of acetaminophen–cysteine adducts in cases of indeterminate liver failure is not diagnostic of intentional overdose

  2011cites this paper
• Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved

  2011cites this paper
• Reply

  2011cites this paper
• Reply

  2011cites this paper
• Reply

  2011cites this paper
• Reply

  2011cites this paper
• Reply

  2011cites this paper
• Reply

  2011cites this paper
• Hepatitis C virus therapeutics: Editing enzymes promising therapeutic targets?

  2011cites this paper